NVAX Stock Surges on COVID-19 Vaccine Development

Novavax stock has surged nearly 240% in 2020

Deputy Editor
Feb 28, 2020 at 1:03 PM
facebook twitter linkedin

Shares of Novavax Inc (NYSE:NVAX) are soaring today, up 12.3%, earlier peaking at $17.71, and last seen at $13.87. The clinical-stage vaccine company earlier in the week announced a COVID-19 vaccine candidate, which they hope to put into phase 1 clinical trial late this spring. NVAX is planning to utilize its proprietary Matrix-M adjuvant with its candidate in the hopes that it will enhance immune responses.

While the global market continues to reel in the wake of the coronavirus outbreak, analysts are mixed on just how to tackle shares of companies with their hands in the perennial vaccination drug-market bag. Currently, five out eight analysts are lying heavily on a “strong buy” recommendation, while two are saying its time to “hold,” and just one sports a “strong sell."

NVAX experienced an odd course of events today as its trading was suddenly halted due to volatility before being resumed shortly thereafter. Currently, NVAX is trading at its highest point since its March 2019 bear gap, though it has a ways to go to mend the pullback. Year-to-date, the equity sports an impressive 239% gain.





Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners